Net profit of Jubilant Ingrevia rose 79.93% to Rs 69.38 crore in the quarter ended December 2024 as against Rs 38.56 crore during the previous quarter ended December 2023. Sales rose 8.91% to Rs 1046.06 crore in the quarter ended December 2024 as against Rs 960.45 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales1046.06960.45 9 OPM %13.229.95 - PBDT135.3489.32 52 PBT95.5855.08 74 NP69.3838.56 80 Powered by Capital Market - Live

Jubilant Ingrevia has fixed 03 February 2025 as record date for the purpose of ascertaining eligibility of the shareholders for payment of interim dividend. The dividend will be paid on or before 26 February 2025. Powered by Capital Market - Live

Jubilant Ingrevia announced that the Board of Directors of the Company at its meeting held on 28 January 2025, has recommended a Interim dividend of Rs.2.50 per share (i.e.250%), subject to the approval of the shareholders.Powered by Capital Market - Live

The new facility, which has a capacity of 5,000 metric tonnes, will manufacture nutraceuticals and dietary-active ingredients for human consumption. The facility is an extension of the company's US FDA approved plant that is already supplying to the U.S., Europe, Japan and many other markets. The Niacinamide from the new plant in addition to its various applications in skin and hair care, will also pave way for the company to foray into infant nutrition market globally, with food grade Niacin. The production of these new grades of Vitamin B3 will significantly enhance the company's presence within value-added products with this high-value and high-margin offering. Deepak Jain, CEO & managing director, Jubilant Ingrevia said: 'The commissioning of our new facility for Niacinamide aimed at food, nutrition and cosmetic applications is an important milestone in our journey. We are already one of the world's largest producers of Niacinamide and as we ramp up the utilisation of this new plant, we aim to become global leader in Vitamin B3 in the coming years. With this, we are now among a select few capable of producing high-quality Vitamin B3 for these high-value, high margin offerings. It also gives us a strategic moat, protecting us from industry volatility in feed-grade Niacinamide. We are pleased to share that we are already in discussions with some of the most recognizable global brands to begin our supplies. Jubilant Ingrevia is a global integrated life science products and innovative solutions provider serving, pharmaceutical, nutrition, agrochemical, consumer and industrial customers with its customised products and solutions that are innovative, cost effective and conforming to premium quality standards. The company is engaged in manufacturing and supply of speciality chemicals, nutrition & health solutions and chemical intermediates through five manufacturing facilities in India. The company's consolidated net profit rose 2.63% to Rs 59 crore on 1.77% increase in revenue to Rs 1029 crore in Q2 FY25 as compared with Q2 FY24. The scrip fell 1.94% to currently trade at Rs 674.05 on the BSE. Powered by Capital Market - Live

Jubilant Ingrevia today announced the commissioning of its new cGMP compliant facility at Bharuch, Gujarat. The new facility will manufacture Nutraceuticals and Dietary-Active ingredients for human consumption. The facility is an extension of the company's USFDA approved plant that is already supplying to the U.S., Europe, Japan and many other markets. It will be fully equipped to cater to the needs of the biggest marquee customers in the food, nutrition and cosmetics space. Customers seeking greener supply chains and high bio-content in their inputs, will especially stand to benefit. The Niacinamide from the new plant in addition to its various applications in skin and hair care, will also pave way for the Company to foray into infant nutrition market globally, with food grade Niacin. The production of these new grades of Vitamin B3 will significantly enhance the Company's presence within value-added products with this high-value and high-margin offering. Powered by Capital Market - Live

Jubilant Ingrevia will hold a meeting of the Board of Directors of the Company on 28 January 2025.Powered by Capital Market - Live

The key equity indices continued to trade in negative terrain with significant losses in the morning trade. The Nifty hovered below the 23,550 mark. Realty shares extended losses for the third consecutive trading session. At 10:30 IST, the barometer index, the S&P BSE Sensex, declined 483.03 points or 0.62% to 77,765.10. The Nifty 50 index dropped 121.65 points or 0.51% to 23,523.25. In the broader market, the S&P BSE Mid-Cap index fell 0.78% and the S&P BSE Small-Cap index declined 0.33%. The market breadth was negative. On the BSE, 1,554 shares rose and 2,020 shares fell. A total of 156 shares were unchanged. New Listing: Shares of Unimech Aerospace and Manufacturing were currently trading at Rs 1,375.85 at 10:18 IST on the BSE, representing a premium of 75.27% as compared with the issue price of Rs 785. The scrip was listed at Rs 1,491, exhibiting a premium of 89.94% to the issue price. So far, the stock has hit a high of 1,491 and a low of 1,355.05. On the BSE, over 4.21 lakh shares of the company were traded in the counter so far. Buzzing Index: The Nifty Realty index lost 0.77% to 1,046.75. The index fell 2.83% in three consecutive trading sessions. Macrotech Developers (down 4.42%), Phoenix Mills (down 2.61%) and Godrej Properties (down 2.14%) declined. On the other hand, Prestige Estates Projects (up 1.11%), Brigade Enterprises (up 0.60%) and Mahindra Lifespace Developers (up 0.59%) edged higher. Stocks in Spotlight: Jubilant Ingrevia advanced 2.64% after the company's wholly owned subsidiary, Jubilant Infrastructure (JIL) board has approved to purchase 6.67% stake in Forum I Aviation Private (FAPL) from Hero Fincorp & Sunil Kant Munjal. KPI Green Energy rose 0.21%. The company said that it has obtained approvals from the chief electrical inspector (CEIG) for 28.28 MW of solar power projects under CPP business segment.Powered by Capital Market - Live

FAPL is engaged in business of operating aircrafts on charter basis under the non-scheduled airlines. It revenue was Rs 27.32 crore in FY24. The purpose of making further investment by Jubilant Infrastructure in FAPL is to meet business requirements. The company will acquire 16.67% at Rs 10.2915 per share. The said transaction is expected to be completed within this financial year. At present JIL holds 9.12% equity shares in FAPL. Post-acquisition, JIL holds 15.79% equity shares in FAPL Jubilant Ingrevia is a global integrated life science products and innovative solutions provider serving, pharmaceutical, nutrition, agrochemical, consumer and industrial customers with its customised products and solutions that are innovative, cost effective and conforming to premium quality standards. The company is engaged in manufacturing and supply of speciality chemicals, nutrition & health solutions and chemical intermediates through five manufacturing facilities in India. The company's consolidated net profit rose 2.6% to Rs 59 crore on 1.8% increase in net sales to Rs 1029 crore in Q2 FY25 over Q2 FY24.Powered by Capital Market - Live

Jubilant Ingrevia has issued commercial paper of Rs 48 crore on 27 December 2024. Powered by Capital Market - Live

Net profit of Jubilant Ingrevia rose 2.63% to Rs 59.00 crore in the quarter ended September 2024 as against Rs 57.49 crore during the previous quarter ended September 2023. Sales rose 1.77% to Rs 1029.00 crore in the quarter ended September 2024 as against Rs 1011.10 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1029.001011.10 2 OPM %12.0911.64 - PBDT119.82113.78 5 PBT80.2279.87 0 NP59.0057.49 3 Powered by Capital Market - Live